Gossamer Bio (NASDAQ:GOSS) Research Coverage Started at Oppenheimer

Oppenheimer initiated coverage on shares of Gossamer Bio (NASDAQ:GOSS) in a research note issued on Tuesday, Marketbeat Ratings reports. The firm set an “outperform” rating and a $9.00 price target on the stock.

Several other brokerages also recently commented on GOSS. The Goldman Sachs Group reiterated a “buy” rating and issued a $8.00 target price on shares of Gossamer Bio in a report on Monday, June 17th. Piper Sandler reiterated an “overweight” rating and issued a $15.00 target price on shares of Gossamer Bio in a report on Wednesday, March 27th. Wedbush reiterated an “outperform” rating and issued a $4.00 target price on shares of Gossamer Bio in a report on Wednesday, May 8th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Gossamer Bio in a research report on Monday, May 20th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.88.

Gossamer Bio Stock Up 27.1 %

Gossamer Bio stock opened at $0.83 on Tuesday. The company has a market capitalization of $186.88 million, a P/E ratio of -0.78 and a beta of 1.91. The firm’s fifty day simple moving average is $0.66 and its 200-day simple moving average is $0.92. The company has a current ratio of 7.13, a quick ratio of 7.13 and a debt-to-equity ratio of 7.37. Gossamer Bio has a 1-year low of $0.45 and a 1-year high of $1.88.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.19) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.19). Sell-side analysts forecast that Gossamer Bio will post -0.35 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Faheem Hasnain sold 23,172 shares of Gossamer Bio stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $1.16, for a total transaction of $26,879.52. Following the sale, the chief executive officer now directly owns 120,293 shares in the company, valued at approximately $139,539.88. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.00% of the stock is owned by company insiders.

Institutional Trading of Gossamer Bio

Several institutional investors have recently made changes to their positions in the business. Sivia Capital Partners LLC acquired a new stake in shares of Gossamer Bio during the 1st quarter valued at about $29,000. Financial Advocates Investment Management boosted its position in Gossamer Bio by 35.0% in the fourth quarter. Financial Advocates Investment Management now owns 98,350 shares of the company’s stock valued at $90,000 after buying an additional 25,500 shares in the last quarter. SG Americas Securities LLC acquired a new position in Gossamer Bio in the first quarter valued at about $34,000. Vanguard Group Inc. boosted its position in Gossamer Bio by 1.1% in the first quarter. Vanguard Group Inc. now owns 11,763,784 shares of the company’s stock valued at $13,881,000 after buying an additional 128,150 shares in the last quarter. Finally, Citigroup Inc. boosted its position in Gossamer Bio by 9,916.9% in the third quarter. Citigroup Inc. now owns 196,732 shares of the company’s stock valued at $164,000 after buying an additional 194,768 shares in the last quarter. 81.23% of the stock is currently owned by institutional investors and hedge funds.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.